Spain Liver Diseases Therapeutics Market Report 2022 to 2030

Spain Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Spain Liver Disease Therapeutics market will reach a value of $644 Mn from $446 Mn in 2022, growing at a CAGR of 4.7% during 2022-2030. Liver Disease Therapeutics in Spain is dominated by a few domestic pharmaceutical companies such as Grifols, Faes Farma, and Laboratorios Rubió. The Liver Disease Therapeutics market in Spain is segmented into different types of disease and different therapy types. Some of the major factors affecting the Spain Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10ESPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Spain AUTHOR: Dr. Vishwa Modhia

Buy Now

Spain Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Spain Liver Disease Therapeutics market will reach a value of $644 Mn from $446 Mn in 2022, growing at a CAGR of 4.7% during 2022-2030.

Spain is a high-income developed country located in Southwestern Europe. The coastlines include the Bay of Biscay, the Mediterranean Sea, and the Northern Atlantic Ocean. According to the latest WHO data published in 2020 Liver Disease Deaths in Spain reached 4,231 or 1.28% of total deaths. The age-adjusted Death Rate is 4.79 per 100,000 population ranks Spain 163^rd in the world.

Alcohol-related liver disease is the most common type of liver disease in Spain, accounting for around half of all liver disease cases, according to the Spanish Association for the Study of the Liver (AEEH). Several public health strategies have been established in Spain to prevent alcohol-related harm and promote liver health. These include alcohol levies, prohibitions on alcohol advertising, and hepatitis B and C screening programmes. Spain's government spent 10.7 % of its GDP on healthcare in 2020.

Spain Liver Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

In 2019, approximately 28,000 people were hospitalised in Spain for liver illness, with an average hospital stay of 9 days. The illness primarily affects men and is most commonly diagnosed in people aged 60 and up. Hepatitis B vaccine coverage in Spain is 93%, reflecting a well-developed healthcare system. Spain's financial assistance from European institutions has steadily increased. Furthermore, the industrial industry in Spain has recently demonstrated its ability to reinvent itself. These aspects could boost Spain Liver Disease Therapeutics market.

Market Restraints

Liver disease therapy frequently necessitates specialised care, such as liver transplant surgery or access to hepatologists. However, in some areas of Spain, these resources may be scarce, resulting in treatment delays or the necessity for patients to travel significant distances to receive care. Spain is extremely vulnerable to pandemic-prone industries. It has a skewed labour market and significant structural unemployment. These factors may deter new entrants into the Spain Liver Disease Therapeutics market.

Competitive Landscape

Key Players

Grifols: Grifols is a Spanish pharmaceutical company that develops and produces a range of therapeutic products, including those for liver disease. Its liver disease products include albumin, immunoglobulins, and coagulation factors
Faes Farma: Faes Farma is a Spanish pharmaceutical company that specializes in the research, development, and commercialization of pharmaceutical products. Its liver disease products include UDCA (ursodeoxycholic acid) and Silibinin
Laboratorios Rubió: Laboratorios Rubió is a Spanish pharmaceutical company that focuses on developing and producing drugs for liver disease. Its liver disease products include UDCA (ursodeoxycholic acid) and Ademetionina
Laboratorios Rovi: Laboratorios Rovi is a Spanish pharmaceutical company that develops and produces a range of therapeutic products, including those for liver disease. Its liver disease products include Heparin and Enoksaparina
Almirall: Almirall is a Spanish pharmaceutical company that focuses on developing and producing drugs for a range of therapeutic areas, including liver disease. Its liver disease products include Ursobilane and Epatikine

Recent Notable Updates

November 2022: Grifols, a global leader in plasma-derived medicines and innovative diagnostic solutions, announced today that its AlphaI At Home Genetic Health Risk Service, the first-ever free direct-to-consumer programme in the United States to screen for genetic risk of alpha1-antitrypsin deficiency (alpha-1) deficiency, has been cleared by the United States Food and Drug Administration (FDA). The service, marketed as AlphaI At Home, is the company's first FDA-approved direct-to-consumer offering. It will be available without a medical prescription for U.S. individuals to screen for their genetic risk level of developing alpha-1-related lung and/or liver illness commencing in Q2 2023.

Healthcare Policies and Reimbursement Scenarios

In Spain, the regulation and reimbursement of liver therapeutics are primarily overseen by the Spanish Agency for Medicines and Medical Devices (AEMPS) and the Spanish National Health System (SNS), respectively. AEMPS is responsible for assessing the safety, efficacy, and quality of liver therapeutics before they can be marketed and used in Spain. In terms of reimbursement, the SNS covers the cost of liver therapeutics for patients who meet certain criteria. The reimbursement process is managed by the Ministry of Health, which determines which therapies are eligible for reimbursement and the conditions under which they will be covered.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.